|
Name |
Calbistrin F
|
Molecular Formula | C28H44O7 | |
IUPAC Name* |
[(1S,3R,4aR,7S,8S,8aS)-8-(3-hydroxypropanoyl)-3,7,8-trimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyldeca-4,6-dienoate
|
|
SMILES |
C[C@@H]1C[C@@H]2C=C[C@@H]([C@]([C@H]2[C@H](C1)OC(=O)[C@@H](C)[C@H](/C(=C/C=C/[C@@H]([C@@H](C)O)O)/C)O)(C)C(=O)CCO)C
|
|
InChI |
InChI=1S/C28H44O7/c1-16-14-21-11-10-18(3)28(6,24(32)12-13-29)25(21)23(15-16)35-27(34)19(4)26(33)17(2)8-7-9-22(31)20(5)30/h7-11,16,18-23,25-26,29-31,33H,12-15H2,1-6H3/b9-7+,17-8+/t16-,18+,19+,20-,21+,22+,23+,25-,26+,28-/m1/s1
|
|
InChIKey |
ZGRACCPMOXYOKT-RXZQRYLVSA-N
|
|
Synonyms |
Calbistrin F; CHEMBL3358712; [(1S,3R,4aR,7S,8S,8aS)-8-(3-hydroxypropanoyl)-3,7,8-trimethyl-2,3,4,4a,7,8a-hexahydro-1H-naphthalen-1-yl] (2S,3R,4E,6E,8S,9R)-3,8,9-trihydroxy-2,4-dimethyl-deca-4,6-dienoate
|
|
CAS | NA | |
PubChem CID | 118723026 | |
ChEMBL ID | CHEMBL3358712 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 492.6 | ALogp: | 3.0 |
HBD: | 4 | HBA: | 7 |
Rotatable Bonds: | 11 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 124.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 35 | QED Weighted: | 0.208 |
Caco-2 Permeability: | -4.98 | MDCK Permeability: | 0.00010983 |
Pgp-inhibitor: | 0.968 | Pgp-substrate: | 0.993 |
Human Intestinal Absorption (HIA): | 0.126 | 20% Bioavailability (F20%): | 0.112 |
30% Bioavailability (F30%): | 0.914 |
Blood-Brain-Barrier Penetration (BBB): | 0.285 | Plasma Protein Binding (PPB): | 50.47% |
Volume Distribution (VD): | 0.437 | Fu: | 16.14% |
CYP1A2-inhibitor: | 0.086 | CYP1A2-substrate: | 0.15 |
CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.795 |
CYP2C9-inhibitor: | 0.019 | CYP2C9-substrate: | 0.285 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.081 |
CYP3A4-inhibitor: | 0.795 | CYP3A4-substrate: | 0.485 |
Clearance (CL): | 6.56 | Half-life (T1/2): | 0.812 |
hERG Blockers: | 0.084 | Human Hepatotoxicity (H-HT): | 0.698 |
Drug-inuced Liver Injury (DILI): | 0.663 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.477 | Maximum Recommended Daily Dose: | 0.022 |
Skin Sensitization: | 0.257 | Carcinogencity: | 0.062 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.031 |
Respiratory Toxicity: | 0.861 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003293 | 0.825 | D02RQU | 0.270 | ||||
ENC003294 | 0.721 | D0E9KA | 0.232 | ||||
ENC003119 | 0.373 | D06WTZ | 0.227 | ||||
ENC004660 | 0.344 | D0X7XG | 0.215 | ||||
ENC003665 | 0.336 | D03JSJ | 0.204 | ||||
ENC003895 | 0.333 | D0F7NQ | 0.201 | ||||
ENC003781 | 0.333 | D0G7KJ | 0.200 | ||||
ENC003792 | 0.330 | D03IKT | 0.200 | ||||
ENC004127 | 0.324 | D0H0ND | 0.199 | ||||
ENC003775 | 0.321 | D05ZTH | 0.196 |